SCHEMBL2568620

SCHEMBL2568620

c1cnc(NC2CCOCC2)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 1.00
KDM4E B2RXH2 1/20 0.64
GAA P10253 1/20 0.64
HDAC3 O15379 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
RET P07949 1/20 0.51
MKNK1 Q9BUB5 2/20 0.49
MKNK2 Q9HBH9 2/20 0.49
HRH4 Q9H3N8 1/20 0.48
DRD2 P14416 4/20 0.46
DRD3 P35462 4/20 0.46
CDC7 O00311 1/20 0.44
DAPK3 O43293 1/20 0.44
JAK2 O60674 1/20 0.44
ROCK2 O75116 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
PAK4 O96013 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987323 0.88 MAPK1 (0.79) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL2569209 0.88 MAPK1 (0.79) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL246119 0.84 KDM4E (0.78) MAPK1KDM4EGAADRD2DRD3
Hydrochloric Acid SCHEMBL1936751 0.82 KDM4E (0.75) MAPK1KDM4EGAADRD2DRD3
SCHEMBL6190784 0.80 KDM4E (0.95) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL12162873 0.80 KDM4E (0.87) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL19144932 0.79 MAPK1 (1.00) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL1256168 0.79 MAPK1 (0.69) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL29730384 0.79 MAPK1 (1.00) MAPK1KDM4EGAAHDAC3HDAC1
SCHEMBL7768908 0.78 KDM4E (1.00) MAPK1KDM4EGAAHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213119-A1 THIENOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CA LID (CN) 2022-07-07 US disclosed
EP-3386494-A1 VAP-1 INHIBITORS FOR TREATING PAIN Benevolentai Cambridge Limited (GB) 2018-10-17 EP disclosed
US-20180201616-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2018-07-19 US disclosed
US-20170197970-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2017-07-13 US disclosed
WO-2017098236-A1 VAP-1 INHIBITORS FOR TREATING PAIN PROXIMAGEN LIMITED (GB) 2017-06-15 WO disclosed
EP-2382013-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2011-11-02 EP disclosed
WO-2010072829-A1 SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197970-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 MAPK1 2996/4885KDM4E 2919/4885GAA 4405/4885
US-20180201616-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 MAPK1 2996/4885KDM4E 2919/4885GAA 4405/4885
US-20220213119-A1 THIENOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF MAPK11, MAPK7, MAPK1 MAPK1 3/4885KDM4E 4034/4885GAA 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.